Open30.330 | Close- |
Vol / Avg.81.255K / 238.673K | Mkt Cap913.162M |
Day Range29.890 - 31.970 | 52 Wk Range27.020 - 59.960 |
Keros Therapeutics Stock (NASDAQ: KROS) stock price, news, charts, stock research, profile.
Open30.330 | Close- |
Vol / Avg.81.255K / 238.673K | Mkt Cap913.162M |
Day Range29.890 - 31.970 | 52 Wk Range27.020 - 59.960 |
Q4 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.350 | -1.330 | 0.0200 | ||||
REV | 8.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-11-13 | Wedbush | Andreas Argyrides | Reiterates | OutperformOutperform | Maintains | - | 86.00 |
2023-08-31 | Wedbush | Andreas Argyrides | Reiterates | OutperformOutperform | Maintains | - | 86.00 |
2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 100.00 |
2023-08-08 | Wedbush | Andreas Argyrides | Reiterates | OutperformOutperform | Maintains | - | 86.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KROS | Keros Therapeutics | 0.46% | 913.2M |
VALN | Valneva | -1% | 798.3M |
ZNTL | Zentalis Pharma | -1.33% | 785.5M |
DAWN | Day One Biopharmaceutical | 3.02% | 1B |
XNCR | Xencor | 0.11% | 1.1B |
You can purchase shares of Keros Therapeutics (NASDAQ: KROS) through any online brokerage.
Other companies in Keros Therapeutics’s space includes: Valneva (NASDAQ:VALN), Zentalis Pharma (NASDAQ:ZNTL), Day One Biopharmaceutical (NASDAQ:DAWN), Xencor (NASDAQ:XNCR) and Tango Therapeutics (NASDAQ:TNGX).
The latest price target for Keros Therapeutics (NASDAQ: KROS) was reported by Wedbush on Monday, November 13, 2023. The analyst firm set a price target for 86.00 expecting KROS to rise to within 12 months (a possible 182.15% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Keros Therapeutics (NASDAQ: KROS) is $30.48 last updated Today at December 1, 2023 at 7:32 PM UTC.
There is no dividend information for Keros Therapeutics.
Keros Therapeutics’s Q4 earnings are confirmed for Friday, March 1, 2024.
There is no upcoming split for Keros Therapeutics.
Keros Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.